Supplementary File 1 Population and probiotic strain and dose in probiotic intervention trials

|  |  |  |  |
| --- | --- | --- | --- |
| **Study ID** | **Diagnosis, sample size** | **Preparation and dose** | **Duration (weeks)** |
| Bausserman 2005 | IBS, n=50 | Lactobacillus rhamnosus GG in capsule form in concentration of 1010 CFU of bacteria with inulin, 1 capsule, 2 x day | 6 |
| Francavilla 2010 | IBS or FAP, n=141 | Lactobacillus rhamnosus GG (3 x 109 CFU), 1 capsule twice per day  | 8 |
| Gawronska 2007 | FD, IBS or FAP, n=104 | Lactobacillus rhamnosus GG (3 x 109 CFU), 1 capsule twice per day  | 4 |
| Kianifar2015 | IBS.n=60 | Lactobacillus rhamnosus GG with a concentration of 1 × 1010 CFU/mL bacteria, 1 capsule twice per day | 4 |
| Sabbi 2011 | FAP, n=61 | Lactobacillus rhamnosus GG (no further details given) | 6 |
| Eftekhari 2015 | RAP, n=80 | Lactobacillus reuteri DSM 17938, 5 drops per day orally equivalent to 108CFU | 4 |
| Romano 2010 | FAP, n=56 | Lactobacillus reuteri DSM 17938, oral supplementation at 108 CFU, twice daily | 4 |
| Weizman 2016 | FGID, n=101 | Lactobacillus reuteri DSM 17938 108 CFU/day once a day as chewable tablets | 4 |
| Young 1997 | RAP, n=11 | Lactobacillus plantarum (LP299V). (no further details given) |  |
| Guandalini 2010 | IBS, n=67 | VSL#3 (contains live, freeze-dried lactic acid bacteria, at a total concentration of 450 billion lactic acid bacteria per sachet, comprising 8 different strains: Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus bulgaris, and Streptococcus thermophiles). 1 sachet once per day for children aged 4 to 11 years and twice a day for children aged 12 to 18 years | 6 |
| Gianetti 2017 | IBS or FD, n=78 | 1 sachet per day of a mixture of 3 Bifidobacterium species (3 billion of B longum BB536, 1 billion of B infantis M-63, 1 billion of B breve M-16V) | 6 |
| Saneiain 2015 | FAP, n=88 | Synbiotic tablets twice daily consisting of the probiotic Bacillus coagulans plus fructo-oligosaccharide (100 mg) | 4 |
| Asgarshirazi 2017 | FGID, n=120 | Synbiotic Lactol tablet (150 million spores of Bacillus coagulans + fructooligosaccharide), 1 tablet, 3 x day | 4 |
| \* Jadresin 2017 | FAP or IBS, n=55 | Lactobacillus reuteri DSM 17938, chewable tablet also containing, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring, and anhydrous citric acid, with a total viable count of 1x108 live bacteria (CFU)/tablet | 12 |
| \* Maragkoudaki 2017 | FAP, n=54 | Lactobacillus reuteri DSM 17938, daily breakfast supplementation with two chewable tablets of either  at a dose of 1×108CFU/ tablet  | 4 |

FAP Functional Abdominal Pain; FD Functional Dyspepsia; FGID Functional Gastrointestinal Disorder; IBS Irritable Bowel Syndrome; RAP Recurrent abdominal pain

\* Studies found on update search (21/11/2017)